GH Research (NASDAQ:GHRS – Get Free Report) and Prenetics Global (NASDAQ:PRE – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
Insider & Institutional Ownership
56.9% of GH Research shares are held by institutional investors. Comparatively, 25.0% of Prenetics Global shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Comparatively, 7.8% of Prenetics Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares GH Research and Prenetics Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GH Research | N/A | -16.30% | -15.77% |
| Prenetics Global | -61.33% | -19.07% | -15.38% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GH Research | 1 | 1 | 9 | 0 | 2.73 |
| Prenetics Global | 1 | 0 | 3 | 0 | 2.50 |
GH Research currently has a consensus target price of $40.13, indicating a potential upside of 118.78%. Prenetics Global has a consensus target price of $32.33, indicating a potential upside of 81.34%. Given GH Research’s stronger consensus rating and higher possible upside, analysts plainly believe GH Research is more favorable than Prenetics Global.
Valuation & Earnings
This table compares GH Research and Prenetics Global”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GH Research | N/A | N/A | -$48.26 million | ($0.80) | -22.93 |
| Prenetics Global | $92.39 million | 3.25 | -$58.32 million | ($4.02) | -4.44 |
GH Research has higher earnings, but lower revenue than Prenetics Global. GH Research is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
GH Research has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Prenetics Global has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.
Summary
GH Research beats Prenetics Global on 10 of the 13 factors compared between the two stocks.
About GH Research
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
